Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc (ACAD) delivers innovative therapies for central nervous system disorders and rare diseases through targeted research and clinical development. This dedicated news hub provides investors and healthcare professionals with essential updates on ACAD's progress in neurology and neuro-rare disease treatments.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Parkinson's Disease Psychosis therapies, Rett syndrome research advancements, and pipeline progress across ACAD's neuroscience portfolio. Each release maintains scientific rigor while remaining accessible to both medical experts and investment analysts.
Key coverage areas include FDA submissions, peer-reviewed study publications, and collaborative research initiatives. Bookmark this page for centralized access to ACAD's latest scientific achievements and operational updates, carefully vetted for accuracy and relevance to long-term therapeutic development.
Acadia Pharmaceuticals has presented new analyses on Medicare claims data related to dementia-related psychosis (DRP) at Psych Congress 2021. The data shows that over 70% of patients treated with off-label atypical antipsychotics experienced adverse events within a year, with costs averaging $5,565 for hyperlipidemia. Additionally, approximately 38% of patients faced cerebrovascular adverse events, with associated costs soaring to $68,308. Furthermore, nearly two-thirds of patients experienced suboptimal treatment outcomes leading to higher annual costs.
Acadia emphasizes the urgent need for effective treatments for DRP.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the promotion of Brendan Teehan to Executive Vice President and Chief Operating Officer, effective immediately. Previously the Senior Vice President, Chief Insights and Analytics Officer, Teehan will oversee all sales and marketing functions while continuing to lead commercial strategy and operations. Teehan has over 25 years of experience in healthcare, having worked with companies like Johnson & Johnson and Amgen. Additionally, two senior executives, Charmaine Lykins and Amanda Morgan, will leave the company for new opportunities.
Acadia Pharmaceuticals will report its third quarter 2021 financial results on
Acadia Pharmaceuticals (NASDAQ: ACAD) announced a scientific presentation on pimavanserin at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for November 9-12, 2021, in Boston, MA. A poster presentation will summarize post-hoc analysis results from the Phase 3 HARMONY trial, focusing on treating hallucinations and delusions in patients with Parkinson’s disease dementia. Although pimavanserin is FDA-approved for Parkinson’s disease psychosis, it is not approved for dementia-related psychosis.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) will participate in several upcoming virtual investor conferences, including the Citi’s 16th Annual BioPharma Virtual Conference on September 10, 2021, Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 13, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021. Live webcasts will be accessible on the company’s website under the investors section, with archived recordings available for a month post-event.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the departure of Elena Ridloff, Chief Financial Officer, effective September 10, 2021, as she transitions to another biopharmaceutical firm. Mark Schneyer, Senior VP of Business Development, will serve as interim CFO while a formal search for a new CFO is conducted. CEO Steve Davis expressed gratitude for Ridloff's contributions to Acadia's growth and the pimavanserin franchise.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 3:00 p.m. Eastern Time. The event will be held virtually, with a live webcast available on Acadia's website, www.acadia-pharm.com. An archived recording will be accessible until September 12, 2021. Acadia specializes in neuroscience, focusing on therapies for Parkinson's disease psychosis and exploring new treatments for dementia-related psychosis and other CNS disorders.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q2 2021 financial results, with NUPLAZID sales reaching $115.2 million, a 5% increase year-over-year. The company is engaging with the FDA regarding pimavanserin for dementia-related psychosis after a recent Type A meeting. However, they face challenges in conducting further subgroup studies. R&D expenses decreased to $56.9 million, while SG&A expenses rose to $96.8 million. Acadia's net loss for Q2 was $43.9 million. Guidance for NUPLAZID sales has been reduced to $480-$515 million due to the pandemic impacting patient visits.
Acadia Pharmaceuticals announced positive results from the Phase 3 HARMONY study, published in the New England Journal of Medicine, evaluating pimavanserin for treating hallucinations and delusions in dementia-related psychosis (DRP). The study, involving 392 patients, showed a 2.8-fold reduction in relapse risk for those continuing pimavanserin compared to placebo (HR=0.35, p=0.005). Pimavanserin also proved well-tolerated with no cognitive decline. This represents a significant advancement in addressing an unmet need, as no FDA-approved treatments exist for DRP.
Acadia Pharmaceuticals (Nasdaq: ACAD) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss these results. Participants can access the call via dial-in numbers or through a live webcast available on Acadia's website. The company continues to focus on neuroscience breakthroughs, particularly in developing therapies for conditions such as dementia-related psychosis and schizophrenia, while also noting the risks associated with drug development.
